Key facts
- This page summarizes Reshma P. Shetty's Form 4 filing for Ginkgo Bioworks Holdings, Inc. (DNA).
- 4 reported transactions and 4 derivative rows are listed below.
- Accepted by SEC: 30 Jul 2026, 16:27.
Key filing fact
Ownership activity is grounded in SEC Form 4 disclosures.
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
Award
Award
Award
Award
Additional SEC filing notes
Footnote F1
Each restricted stock unit ("RSU") represents a contingent right to receive one share of the Issuer's Class A Common Stock.
Footnote F2
The RSUs were approved by the Compensation Committee of the Board of Directors on July 28, 2026 and shall vest as follows: 75% on October 16, 2026 and 25% on January 21, 2027.
Footnote F3
The RSUs were approved by the Compensation Committee of the Board of Directors on July 28, 2026 and shall vest in equal quarterly installments over the next 12 quarters, with the first vesting to occur on October 16, 2026.
SEC remarks
President & Founder